scholarly article | Q13442814 |
P2093 | author name string | Martuza RL | |
Miyatake S | |||
Rabkin SD | |||
P433 | issue | 4 | |
P921 | main subject | vector-borne disease | Q2083837 |
P304 | page(s) | 222-228 | |
P577 | publication date | 1997-07-01 | |
P1433 | published in | Cancer Gene Therapy | Q15763088 |
P1476 | title | Defective herpes simplex virus vectors expressing thymidine kinase for the treatment of malignant glioma | |
P478 | volume | 4 |
Q36325239 | Current immunotherapeutic strategies for central nervous system tumors |
Q37103315 | Feasibility of herpes simplex virus type 1 mutants labeled with radionuclides for tumor treatment |
Q42360056 | Functional coexpression of HSV-1 thymidine kinase and green fluorescent protein: implications for noninvasive imaging of transgene expression |
Q33995752 | HSV-1-based vectors for gene therapy of neurological diseases and brain tumors: part II. Vector systems and applications |
Q28476019 | Inhibition of glioblastoma growth by the thiadiazolidinone compound TDZD-8 |
Q33618760 | Progression of motor deficits in glioma-bearing mice: impact of CNF1 therapy at symptomatic stages |
Q34786262 | Replication-competent herpes simplex virus vector G207 and cisplatin combination therapy for head and neck squamous cell carcinoma. |
Q92966660 | Rodent Glioma Models: Intracranial Stereotactic Allografts and Xenografts |
Q37269915 | Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUC1 antigen. |
Q35189981 | The bacterial protein toxin, cytotoxic necrotizing factor 1 (CNF1) provides long-term survival in a murine glioma model |
Search more.